Maximum Strength Estimate of Quadriceps and Brachial Biceps Muscles in Patients with Chronic Heart Disease

D.O.I: https://doi.org/10.4127/jbe.2017.0123

SCARPA STEFANO, Ph.D

1 Department of Sport Sciences and Education, University of Padua, Italy

ABSTRACT

Patients diagnosed with heart disease display diminished exercise tolerance, which can be attributed not only to a reduction in aerobic capacity but probably also to a strength deficit. The aim of this study was to estimate maximum dynamic strength of the quadriceps and the brachial biceps muscles in patients affected by chronic heart disease.

Maximum strength was estimated by means of sub-maximal tests in 30 healthy sedentary volunteers and 140 male patients with chronic heart disease: 52 patients with coronary artery disease (CAD); 72 patients diagnosed with chronic heart failure (CHF); 16 patients who had undergone heart transplant (HT).

Maximum strength estimate of the two muscles tested was significantly lower in patients diagnosed with heart disease compared to the control group. When patients were subdivided according to the type of disease, a clear trend among groups was displayed with maximum strength being higher in controls, followed by the CAD group, then the CHF group, and the HT group.

In conclusion it seems possible to assert that maximum strength of both the muscle groups examined is significantly lower in patients diagnosed with cardiovascular disease than in

Key Words: Heart disease, Coronary angioplasty, Heart failure, Heart transplant, Maximum strength, Quadriceps, Brachial biceps
control subjects. Moreover, chronic cardiovascular patients are characterized by a muscular impairment that parallels the history of the disease. This information should be kept in mind when planning a rehabilitation program.

INTRODUCTION

Muscular strength is a fundamental component of exercise and functional capacity, particularly in patients with chronic disease. Muscular strength is positively related to independence, quality of life and ability to perform activities of daily living; and it play also a crucial role in reducing disability and in the prevention of chronic disease1,2.

Patients diagnosed with chronic heart disease display diminished exercise tolerance. This can be attributed not only to a reduction in aerobic capacity, as has been amply demonstrated in the literature3, but probably also to a strength deficit such as muscle structure alterations, including muscle weakness and volume reduction, and other pathophysiological mechanisms that underlie both aerobic and strength. The result is that exercise intolerance is a common clinical manifestation in cardiovascular patients4.

Indeed, back in the early 1990s, Drexler demonstrated that patients diagnosed with chronic heart failure (CHF) exhibit a particular pattern of myopathy characterized by muscular atrophy and a shift in the distribution of fiber type with a reduced oxidative capacity5. The initial loss of type I fibers, which is responsible for endurance, is followed by a consecutive increase in type II fibers. While until not long ago three types of muscle fibers were identified (I; IIa; IIb), currently fibers of the skeletal muscle are classified into four types according to their biochemical characters: (a) slow-twitch type I fatigue-resistant fibers; (b) fast-twitch type IIa fatigue-resistant fibers; (c) fast-twitch type IIx fibers with intermediate fatigue-resistance; (d) and fast-twitch type IIb fatigable fibers6.

Recently, Katsuki et al. (2015) demonstrated the activation of Wnt signaling inducted by C1q that seems contributes to fiber type shift toward fatigable fiber. So fiber type shift toward more fatigable type IIb fiber is one of the characteristics observed during the development of skeletal myopathy in cardiovascular patients7.

Besides all this, the story of illness leads the patient to a sedentary lifestyle then to atrophy and muscle weakness, and consequently to a “cascade” of events responsible for the diminished exercise tolerance and strength deficit. Strength decreases with the severity of disease for reasons that are in part explained (see above) and in part still unknown.

Poor muscle strength is associated with mortality: persons with poorer baseline strength are more likely to die over a follow-up period of 30 years. Although the
mechanism explaining the association between muscle strength and mortality risk remains to be explored, probably the risk of mortality is due to low levels of muscle mass.

Maximum strength of the quadriceps muscle in patients with CHF is an important prognostic index; indeed, in the opinion of some, it is superior to the VO₂max. Handgrip strength can predict long term mortality in patients with CHF and 6-month mortality in population with coronary artery disease (CAD). Other studies found that muscle strength in men without heart disease was inversely and independently associated with all-cause mortality.

While muscular impairment in CHF patients has been amply studied, there are limited case-reports on the strength characteristics of patients affected by other cardiovascular pathologies, such as CAD without ventricular dysfunction. Less attention has been directed also to the issue of post heart transplant (HT) functional capacity.

This study presents many novelty and innovative elements: (a) to recognize the importance of muscle strength as a health component in heart patients (not only the aerobic component as in the past); (b) to establish a method for the assessment of strength based on estimation of 1RM: (b₁) allowing partial information on the severity and history of the disease, (b₂) establishing a targeted rehabilitation program (based on % of 1RM), (b₃) presenting a protocol that is replicable at any medical sports center or gymnasium (being able to establish the baseline and to compare the various diseases on a cross sectional design as well as improvements of each patient in a longitudinal direction (other studies have not found who set out with the same goal as will be explained in the discussion stage).

Taking into account all these premises, the aim of this study was therefore to estimate maximum dynamic strength of the two primary antigravity muscles of upper and lower limbs (the quadriceps and the brachial biceps) in three categories of patients with chronic heart disease: CAD, CHF and HT.

METHODS

Subjects involved

Our study population consisted of 30 healthy sedentary (people who practice less than 150 minutes of moderate-intensity aerobic physical activity throughout the week) volunteers with no previous muscle strength training experience and 140 consecutive male patients with chronic cardiovascular disease who were referred to the sports medicine unit of Noale in Venice for a comprehensive rehabilitation program.
i. 52 patients coronary artery disease (CAD) who had undergone revascularization (coronary angioplasty) for at least two-vessel disease at least 15 days earlier, and/or had suffered re-stenosis.

ii. 72 patients diagnosed with chronic heart failure (CHF) whose clinical condition has been stable for at least 3 months, NYHA classes II – III.

iii. 16 patients who had undergone HT at least 6 months earlier.

All patients were in stable medical condition and were receiving standard medical treatment. 36 participants out of the 140 cardiovascular patients were also diagnosed with diabetes. Written informed consent was obtained from all participants. Patients and control characteristics are given in Table 1.

### Table 1

*Age and anthropometric characteristics of patients and controls.*

<table>
<thead>
<tr>
<th></th>
<th>Number</th>
<th>Age (years)</th>
<th>Height (cm)</th>
<th>Weight (kg)</th>
<th>BMI</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patients</strong></td>
<td>140</td>
<td>59.2±11.9</td>
<td>170.1±7.8</td>
<td>82.5±14.5</td>
<td>28.5±4.3</td>
</tr>
<tr>
<td>CAD</td>
<td>52</td>
<td>59.4±10.1</td>
<td>170.1±6.3</td>
<td>86.7±13.6</td>
<td>29.9±4.1</td>
</tr>
<tr>
<td>CHF</td>
<td>72</td>
<td>60.4±11.7</td>
<td>170.4±8.6</td>
<td>80.5±13.8</td>
<td>27.7±4.1</td>
</tr>
<tr>
<td>HT</td>
<td>16</td>
<td>58.3±12.3</td>
<td>169.6±8.9</td>
<td>78.1±17.6</td>
<td>27.0±4.9</td>
</tr>
<tr>
<td><strong>Controls</strong></td>
<td>30</td>
<td>58.8±7.3</td>
<td>170.0±9.0</td>
<td>77.8±12.2</td>
<td>26.8±3.1</td>
</tr>
</tbody>
</table>

### Strength evaluation

The maximum strength of the quadriceps and the brachial biceps muscles was assessed by means of sub-maximal tests. The tests were deemed appropriate when, for a given load, the subject was able to carry out 10 or fewer repetitions of the movement before fatigue. Once the load and the number of repetitions valid for the test had been established, the following indirect formula was used to calculate the value of 1 repetition maximum (1 RM): Predicted 1 RM = Weight Lifted/1.0278-.0278X (where X is the number of reps performed) [17].

Therefore, predicted 1 RM refers to the maximum weight estimate a person can lift only once in a complete range of motion [17]. Maximum strength of each muscle was obtained through the normalization of 1 RM (kg) by body weight (kg) to avoid the influence of other variables such as muscle mass [9]. Average strength of the muscles of both right and left limbs was considered. During testing, the patient’s electrocardiogram was constantly monitored telemetrically.
Strength testing, in which each exercise involves a contraction phase and a relaxation phase of 2 seconds, comprised:

i. **Single-leg push at the leg-press** (assessment of quadriceps muscle). The patient sits on the horizontal leg-press with the back-rest inclined at an angle of 45° and places the foot of the leg under assessment against the foot-board in such a way that the femur and tibia form a 90° angle.

ii. **One-arm concentrated curl with dumbbells** (assessment of the brachial biceps muscle). The patient sits on a chair without arms, with his/her feet apart and placed firmly on the floor, and with his/her trunk straight and leaning forward; the arm under examination is extended downwards so that the elbow rests against the inside of the ipsilateral thigh just above the knee. The patient then curls the forearm up towards the upper arm while keeping the elbow still.

Before the measurement began, the subjects were instructed to warm up for about 10 min (including 5 min of cycling and 5 min of mobility and free movements of the arms and legs). After warming up, the subjects were familiarized with the device by performing 8-10 repetitions at the lowest load, then the load was gradually increased until reaching the optimal load. All tests were performed by the same two technicians. Only moderate standardized verbal encouragement was given to all participants during the test.

**Statistical Analysis**

All data were processed using the SPSS 18.0 program. Age and anthropometric characteristics are expressed as mean value ± standard deviation. Comparisons between groups were analyzed by unpaired t test (2-sided) or Analysis of variance (one-way ANOVA) for comparisons with >2 subgroups. Bonferroni post-hoc multiple comparisons were performed when appropriate. The alpha-error probability was set at p<.05 (2-sided). When examining the difference between two conditions, effect size was calculated using Cohen’s $d$. When variables were more than two, effect size was calculated using eta squared ($\eta^2$).

**RESULTS**

Group comparisons between patients overall and controls are shown in Figure 1 [±95% confidence interval]. Maximum strength of quadriceps muscles was significantly lower in patients ($M=1.76; SD=.59$) compared to the control group ($M=2.46; SD=.62$) with a difference of 28% ($p=.0001; d=1.15$). Maximum strength of brachial biceps muscle was significantly lower in patients ($M=.19$;
SD=.03) compared to the control group (M=.13; SD=.03) with a difference of 32% (p<.0001; d=2.00).

One-way ANOVA showed between-group differences in maximum strength of both quadriceps ($F_{1,169}=14.37, p=.0001$) and brachial biceps ($F_{1,169}=27.21, p=.0001$) muscles as shown in Table 2.

When patients were subdivided according to the type of disease, although strength differences were not always significant, a clear trend among groups was displayed with maximum strength being higher in controls, followed by the CAD group, then the CHF group, and the HT group as shown in Figure 2 [±95% confidence interval].

The group of patients diagnosed with diabetes did not differ from other patients in maximum strength of both quadriceps (p = .06) and brachial biceps (p = .06) muscles respectively.

### Table 2

Maximum strength estimate of quadriceps and brachial biceps: Comparisons between patients and controls.

<table>
<thead>
<tr>
<th></th>
<th>CONTROLS</th>
<th>CAD</th>
<th>CHF</th>
<th>HT</th>
<th>ANOVA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>M±SD</td>
<td>M±SD</td>
<td>M±SD</td>
<td>M±SD</td>
<td>F</td>
</tr>
<tr>
<td>Quadriceps</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 RM (kg)</td>
<td>190±53</td>
<td>174±56</td>
<td>141±46</td>
<td>96±34</td>
<td>11.71</td>
</tr>
<tr>
<td>1 RM / Weight</td>
<td>2.46±.62</td>
<td>1.98±.67</td>
<td>1.71±.48</td>
<td>1.18±.29</td>
<td>14.37</td>
</tr>
<tr>
<td>Brachial biceps</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 RM (kg)</td>
<td>15±2.7</td>
<td>12±1.9</td>
<td>11±2.8</td>
<td>8.5±3.1</td>
<td>19.97</td>
</tr>
<tr>
<td>1 RM / Weight</td>
<td>.19±.03</td>
<td>.15±.03</td>
<td>.13±.03</td>
<td>.11±.03</td>
<td>27.21</td>
</tr>
</tbody>
</table>

**DISCUSSION**

Cardiovascular rehabilitation is a well-established means of improving the functional capacity, physiological outcomes, quality of life and psychological well-being in patients with cardiovascular disease\textsuperscript{18-20}. Resistance training is now recommended as a component of cardiac rehabilitation by the major guidelines\textsuperscript{1,2,19}. As it happen in aerobic training, for a correct strength training prescription, it is necessary to be aware of the baseline status of the patients in order to develop...
a training program that effectively stresses peripheral muscles without creating cardiovascular overload. To our knowledge, no previous studies compared the baseline strength status in different types of chronic heart disease. Therefore, the purpose of the present study was to estimate maximum dynamic strength of the two primary antigravity muscles of upper and lower limbs in three categories of patients with chronic heart disease: CAD, CHF, and HT.

Unlike most of the studies reported in the literature, which have utilized isokinetic testing, our study evaluated patients by means of a different technique. We decided to evaluate dynamic maximum strength estimating 1 RM (using free weights and a machine) rather than assessing isokinetic force, work, and power or isometric force. Our decision was dictated by the need to utilize an isotonic test that would be both simple and which would require inexpensive equipment that enabled researchers or clinicians to identify the training work-load and to formulate strength training prescriptions to be implemented not only in hospital but also in local gymnasiums.

Strength assessment revealed that the maximum strength of the heart disease patients was 28-32% less than that of a control group of age-matched healthy sedentary subjects (see Figure 1). This should come as no surprise since patients with chronic heart disease often experience impairment, functional limitation and disability due to deteriorating health. Since our patients expressed a great variability in type of disease, disease severity, and in the concurrence of other chronic conditions we decided to estimate maximum strength according to the type of heart disease.

Fig. 1. Maximum strength estimate of the patients enrolled compared with a control group (±95% confidence interval: mean ± 2 standard error of mean). Note. *p < .001.
When the patients were subdivided according to the disease, it clearly emerged that the strongest patients with regard to both the muscle groups were those in the CAD group, followed by CHF group, and then the HT group (see Figure 2). This is the logical consequence of the history of the disease. Indeed, patients who undergo angioplasty often come in for the procedure without having ever suffered from any symptoms that might prompt them to limit their physical effort, or else with symptoms of recent onset. Moreover, hospitalizations are usually very short. At any rate, although CAD group was found to be the strongest group in patient sample, maximum strength of the lower limbs was significantly lower (19%) than that of the control group. This finding seems to confirm the data of previous studies on strength in patients diagnosed with coronary disease: Ghroubi reported a 25% strength deficit in the lower limbs on isokinetic testing\textsuperscript{21} and Gayda a diminished resistance to isometric effort\textsuperscript{22}. The small discrepancy between the studies may be accounted for by the differences in strength testing technique as well as the control group: while we enrolled age matched healthy sedentary subjects with no previous muscle strength training experience, the above mentioned studies compared the patients to a group of physically active age matched controls.

![Fig. 2. Comparison between maximum strength of the patients enrolled subdivided according to the type of disease and the control group (±95% confidence interval: mean ± 2 standard error of mean).](image)

Note.* significantly lower than control (p<.001); ** significantly lower than control (p<.05); † significantly lower than CAD (p<.001); † † significantly lower than CAD (p<.05); ‡ significantly lower than CHF (p<.05).
The natural history of patients diagnosed with CHF is different: repeated hospitalizations together with the pivotal symptoms of heart failure, asthenia and effort dyspnea, prompt patients to limit themselves with regard not only to strenuous effort but also to moderate activity, even to the extent of impairing normal everyday actions in patients with longstanding disease. To this, we may add the effect of malnutrition, which complicates the clinical picture in patients who are in the most advanced functional class\textsuperscript{23}. So, the fact that this group of patients reported a strength deficit of about 31% compared to the control group, is not surprising.

HT patients seem to be the weakest of all, even if data are not always significant owing to the small size of the sample and the variability in years of disease prior to the transplant. Nevertheless, HT is often an effective treatment option for patients with end-stage CHF. Most patients who undergo transplantation spend long periods in bed before the operation. Muscular weakness and fatigue are the primary limiting symptoms in the day to day activities of many of these patients. Moreover, the immunosuppressive and cortisone therapy required after transplantation weakens the muscles further. Back in the 1993, Braith \textit{et al.} \textsuperscript{24} estimated that the quadriceps muscle strength of patients with HT is 60-70% of that in age-matched controls. Our study seems to consolidate this data but with a lower estimate of the deficit in HT recipients (52%).

Summarizing, the present study showed that chronic cardiovascular patients are characterized by a muscular impairment that parallels the history of the disease: baseline strength status decreases with the increase of the disease severity.

To our knowledge, no previous studies measured maximum strength of small muscle groups in patients with chronic heart disease. The novelty of this study was not only to estimate the maximum strength of the quadriceps but also that of the brachial biceps in three categories of patients with chronic heart disease (CAD, CHF, and HT), which showed a similar trend of quadriceps muscle.

**IMPLICATIONS**

Resistance training is not only safe and practicable\textsuperscript{25} but it also plays a crucial role in cardiovascular rehabilitation setting. It has a lot of benefits such as enhancing muscular strength, functional capacity, independence, quality of life and reducing disability\textsuperscript{17}. This study shows that patients with chronic heart disease have a strength impairment which parallels the history of disease. In our opinion this peripheral de-conditioning requires a different approach in the rehabilitation setting. Different types of heart disease show a different trend of strength: it is therefore necessary to evaluate the strength baseline status to be able to train strength, identifying the most appropriate work-load. A strength training with lower
loads for a more prolonged period of time seems advisable in the local gymnasium setting. This lower intensity phase should yield an initial aerobic and strength reconditioning which is recommended before switching to higher intensity training.

LIMITATIONS

This study only considered male patients. We did not include females in the analysis because there were few patients and unequally distributed among the diseases. Moreover, our population comprised only 16 heart transplant patients. Differences in history of disease and functional impairment in these patients require a much higher number of cases for a statistical sample.

Finally, this study presents other two limitations: a lack of data on body composition, and specifically on lean body mass; muscle biopsy was not performed to report on muscle physiology.

CONCLUSIONS

The maximum strength of both quadriceps and the brachial biceps muscles is significantly lower in patients diagnosed with chronic heart disease than in healthy control subjects. Moreover, it seems that chronic cardiovascular patients are characterized by a muscular impairment that parallels the history of the disease. This information should be kept in mind when planning a rehabilitation program.

ACKNOWLEDGMENTS

The study was held at the sports medicine unit of the Noale – Venice in collaboration with the University of Padua, within the project entitled “A multidisciplinary approach to prevention of cardiovascular disease: exercise prescription in the cardiovascular patient”, coordinated by Dr. Patrizio Sarto, and with the support of CassaMarca Foundation - Treviso and the Foundation for the research and treatment of cardiovascular diseases – Mirano.
REFERENCES


Address for correspondence:
Stefano Scarpa,
E-mail: stefano.scarpa.unipd@gmail.com or stefano.scarpa@unipd.it